文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

脓毒性休克早期使用去甲肾上腺素:更新的系统评价与荟萃分析及试验序贯分析

Early norepinephrine for patients with septic shock: an updated systematic review and meta-analysis with trial sequential analysis.
PubMed 文献 · Crit Care · 2025-05-06
一句话结论在脓毒性休克成人中,早期启动去甲肾上腺素与ICU死亡率降低相关(RCT:OR 0.49,95%CI 0.25-0.96),但试验序贯分析提示仍需进一步RCT确认。

该系统评价与荟萃分析纳入10项研究(2项RCT、3项倾向评分匹配研究、5项观察性研究),共4767例脓毒性休克成人患者,比较早期与非早期启动去甲肾上腺素对预后的影响。RCT中早期去甲肾上腺素显著降低ICU死亡率(OR 0.49,95%CI 0.25-0.96),RCT与PSM合并(OR 0.65,95%CI 0.42-0.99)及观察性研究(OR 0.71,95%CI 0.54-0.94)也显示死亡率降低。亚组分析显示乳酸≤3mmol/L及1小时内给药时死亡率降低。早期组6小时液体量减少、达标MAP时间更短、无机械通气天数更多、累积去甲肾上腺素剂量更小。试验序贯分析提示证据尚不充分,仍需进一步RCT确认。

要点

  • 在RCT中,早期启动去甲肾上腺素显著降低脓毒性休克成人ICU死亡率(OR 0.49,95%CI 0.25-0.96;I²=45%,p=0.04)。
  • RCT与PSM研究合并显示早期去甲肾上腺素降低死亡率(OR 0.65,95%CI 0.42-0.99;I²=74%,p=0.05),观察性研究亦显示降低(OR 0.71,95%CI 0.54-0.94;I²=66%)。
  • 亚组分析显示,当乳酸≤3mmol/L且在1小时内给予去甲肾上腺素时死亡率降低。
  • 早期组6小时液体量减少(RCT+PSM:平均差-502 mL,95%CI -899至-106),达标MAP时间更短(平均差-1.30小时,95%CI -1.75至-0.85),无机械通气天数更多(平均差3.99天,95%CI 2.42-5.57)。
  • 试验序贯分析提示目前证据尚不充分,仍需进一步RCT确认上述发现。

适用人群与场景

  • 成人脓毒性休克患者,来自纳入的随机对照试验、倾向评分匹配研究和观察性研究。
  • 研究比较早期启动去甲肾上腺素与非早期启动去甲肾上腺素,研究对象为急性循环衰竭患者。

研究设计与关键结果

  • 研究类型为更新的系统评价与荟萃分析,纳入10项研究(2项RCT、3项倾向评分匹配研究、5项观察性研究),共4767例患者。
  • 主要终点ICU死亡率:RCT中早期去甲肾上腺素组显著降低(OR 0.49,95%CI 0.25-0.96;I²=45%,p=0.04);RCT与PSM合并(OR 0.65,95%CI 0.42-0.99;I²=74%,p=0.05);观察性研究(OR 0.71,95%CI 0.54-0.94;I²=66%)。
  • 亚组分析显示乳酸≤3mmol/L及1小时内给药时死亡率降低。
  • 次要终点:早期组6小时液体量减少(RCT+PSM:平均差-502 mL,95%CI -899至-106;I²=91%,p=0.01);达标MAP时间更短(RCT+PSM:平均差-1.30小时,95%CI -1.75至-0.85;I²=0%,p<0.01);无机械通气天数更多(RCT+PSM:平均差3.99天,95%CI 2.42-5.57;I²=32%,p<0.01);观察性研究中累积去甲肾上腺素剂量更小(平均差-3.44 mcg/kg,95%CI -6.13至-0.76;I²=0%,p=0.01)。
  • 试验序贯分析提示需要更多数据。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入2项RCT、3项倾向评分匹配研究和5项观察性研究。
  • 局限:试验序贯分析提示仍需进一步RCT确认这些发现。

对床旁实践的改变

  • 作者认为,在脓毒性休克中早期引入去甲肾上腺素与死亡率降低、6小时液体量减少、达标MAP时间更快及无机械通气天数更多相关。
  • 作者指出,试验序贯分析提示仍需进一步RCT确认这些发现。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The optimal timing for initiating norepinephrine in septic shock is debated. This updated systematic review and meta-analysis aimed to evaluate the impact of early versus delayed norepinephrine initiation on mortality and clinical outcomes in adults with septic shock.

METHODS: A systematic search in Pubmed, EMbase and the Cochrane Library to identify eligible randomized controlled trials, propensity score matching (PSM) and observational studies that compare early norepinephrine initiation with non-early norepinephrine initiation in patients with acute circulatory failure. The primary outcome was mortality in intensive care unit. Secondary outcomes included intensive care unit length of stay, fluid volume received at 6 h, norepinephrine dose, mechanical ventilation-free days, renal replacement therapy free days, and time to achieve a targeted mean arterial pressure (MAP). Meta-analysis and subgroup analysis were conducted to calculate odds ratio (OR) or mean difference with 95% confidence interval (95%CI) using random-effect model. Trial sequential analysis was conducted to evaluate the conclusiveness of evidence.

RESULTS: Ten studies (two RCT, three PSM and five observational studies) involving 4767 patients were included. Early norepinephrine significantly reduced mortality in RCT (OR 0.49, 95%CI 0.25-0.96; I2 = 45%, p = 0.04), pooled RCT and PSM (OR 0.65, 95%CI 0.42-0.99; I2 = 74%, p = 0.05), and observational studies (OR 0.71, 95%CI 0.54-0.94; I2 = 66%). The trial sequential analysis indicated more data are needed. Subgroup analyses showed reduced mortality with early norepinephrine when lactate was ≤ 3mmol/L and administered within 1 h. Secondary outcomes showed a reduced fluid volume at 6h (RCT + PSM: mean difference -502 mL, 95%CI -899 to -106; I2 = 91%, p = 0.01), faster MAP target achievement (RCT + PSM: mean difference -1.30h, 95%CI -1.75 to -0.85; I2 = 0%, p < 0.01), more mechanical ventilation-free days (RCT + PSM: mean difference 3.99 days, 95%CI 2.42-5.57; I2 = 32%, p < 0.01) and smaller cumulative norepinephrine dose (Observational: mean difference -3.44 mcg/kg, 95%CI -6.13 to -0.76; I2 = 0%, p = 0.01) in the early initiation group compare to the non-early initiation group.

CONCLUSION: Early norepinephrine introduction in septic shock is associated with reduced mortality, decreased fluid volume administered at 6 h, faster time to achieve MAP target and more mechanical ventilation-free days. However, the trial sequential analysis indicates that further RCT are still needed to confirm these findings.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Shi R, Braïk R, Monnet X, et al. Early norepinephrine for patients with septic shock: an updated systematic review and meta-analysis with trial sequential analysis. Crit Care. 2025. PMID: 40329359. doi:10.1186/s13054-025-05400-z

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。